Newamsterdam pharma company n.v.NAMS.US Overview
US StockHealthcare
(No presentation for NAMS)
NAMS Overall Performance
NAMS AI Analysis & Strategy
NAMS Recent Performance
-0.38%
Newamsterdam pharma company n.v.
0.81%
Avg of Sector
-1.14%
S&P500
NAMS PowerScanner
NAMS Key Information
NAMS Valuation Metrics
NAMS Earnings Table
NAMS Profile
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.